Aurinia Pharmaceuticals (AUPH) Expected to Post Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Aurinia Pharmaceuticals to announce earnings of $0.19 per share and revenue of $80.4480 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The business had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. On average, analysts expect Aurinia Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Down 1.7%

Aurinia Pharmaceuticals stock opened at $14.96 on Wednesday. The firm has a 50 day moving average price of $15.98 and a 200-day moving average price of $15.35. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals has a twelve month low of $8.80 and a twelve month high of $19.25. The company has a market capitalization of $1.92 billion, a P/E ratio of 6.89 and a beta of 1.41.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 343,620 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was purchased at an average price of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the purchase, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at approximately $196,166,183.28. This trade represents a 2.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 814,606 shares of company stock worth $12,455,129 in the last three months. 10.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Aurinia Pharmaceuticals by 864.5% during the 4th quarter. Corient Private Wealth LLC now owns 275,472 shares of the biotechnology company’s stock valued at $4,394,000 after acquiring an additional 246,912 shares during the period. nVerses Capital LLC bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $406,000. Uniplan Investment Counsel Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 31.3% in the fourth quarter. Uniplan Investment Counsel Inc. now owns 120,202 shares of the biotechnology company’s stock worth $1,917,000 after acquiring an additional 28,645 shares during the period. Voloridge Investment Management LLC grew its position in shares of Aurinia Pharmaceuticals by 44.3% in the fourth quarter. Voloridge Investment Management LLC now owns 739,444 shares of the biotechnology company’s stock valued at $11,794,000 after purchasing an additional 226,875 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Aurinia Pharmaceuticals by 4.7% in the fourth quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company’s stock valued at $857,000 after purchasing an additional 2,421 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on AUPH. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings lowered Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.